Altman Z Score is one of the simplest fundamental models to determine how likely your company is to fail. The module uses available fundamental data of a given equity to approximate the Altman Z score. Altman Z Score is determined by evaluating five fundamental price points available from the company's current public disclosure documents. Please check Pfizer Piotroski F Score and Pfizer Valuation analysis.
Search Z Score
Pfizer
Z Score
Net Income Per Employee
Revenue Per Employee
Average Assets
Earnings Before Interest Taxes and Depreciation Amortization EBITDA
Earnings Before Interest Taxes and Depreciation Amortization USD
Earnings before Tax
Average Equity
Enterprise Value
Free Cash Flow
Invested Capital
Invested Capital Average
Market Capitalization
Tangible Asset Value
Working Capital
Interest Coverage
Long Term Debt to Equity
Calculated Tax Rate
PPandE Turnover
Receivables Turnover
Inventory Turnover
Accounts Payable Turnover
Accrued Expenses Turnover
Operating Margin
Cash and Equivalents Turnover
Return on Investment
Cash Flow Per Share
Revenue to Assets
Total Assets Per Share
Quick Ratio
Net Current Assets as percentage of Total Assets
Asset Turnover
Book Value per Share
Current Ratio
Debt to Equity Ratio
Dividend Yield
Dividends per Basic Common Share
EBITDA Margin
Earnings per Basic Share
Earnings per Diluted Share
Earnings per Basic Share USD
Enterprise Value over EBIT
Enterprise Value over EBITDA
Free Cash Flow per Share
Gross Margin
Profit Margin
Payout Ratio
Price to Book Value
Price to Earnings Ratio
Price to Sales Ratio
Return on Average Assets
Return on Average Equity
Return on Invested Capital
Return on Sales
Sales per Share
Tangible Assets Book Value per Share
Capital Expenditure
Depreciation Amortization and Accretion
Net Cash Flow or Change in Cash and Cash Equivalents
Net Cash Flow Business Acquisitions and Disposals
Issuance Purchase of Equity Shares
Issuance Repayment of Debt Securities
Payment of Dividends and Other Cash Distributions
Net Cash Flow from Financing
Net Cash Flow from Investing
Net Cash Flow Investment Acquisitions and Disposals
Net Cash Flow from Operations
Effect of Exchange Rate Changes on Cash
Share Based Compensation
Inventories
Receivables
Accounts Payable
Accumulated Other Comprehensive Income
Total Assets
Current Assets
Assets Non Current
Cash and Equivalents
Cash and Equivalents USD
Total Debt
Debt Current
Debt Non Current
Total Debt USD
Shareholders Equity
Shareholders Equity USD
Goodwill and Intangible Assets
Inventory
Investments
Investments Current
Investments Non Current
Total Liabilities
Current Liabilities
Liabilities Non Current
Trade and Non Trade Payables
Property Plant and Equipment Net
Trade and Non Trade Receivables
Accumulated Retained Earnings Deficit
Tax Assets
Tax Liabilities
Direct Expenses
Consolidated Income
Cost of Revenue
Earning Before Interest and Taxes EBIT
Earning Before Interest and Taxes USD
Gross Profit
Net Income
Net Income Common Stock
Net Income Common Stock USD
Net Loss Income from Discontinued Operations
Net Income to Non Controlling Interests
Operating Expenses
Operating Income
Revenues
Revenues USD
Research and Development Expense
Selling General and Administrative Expense
Weighted Average Shares
Weighted Average Shares Diluted
Income Tax Expense
Probability Of Bankruptcy
Refresh
The current year Market Capitalization is expected to grow to about 225.4 B, whereas Capital Expenditure is expected to decline to (2.8 B). Pfizer Net Income to Non Controlling Interests is expected to increase significantly based on the last few years of reporting. The past year's Net Income to Non Controlling Interests was at 29 Million. The current year Operating Income is expected to grow to about 12.4 B, whereas Cost of Revenue is expected to decline to about 9.9 B.
Pfizer Z Score Analysis
Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
To calculate Z-Score one would need to know current working capital of the company, its total assets, and liabilities, amount of latest retained earnings as well as earnings before interest and tax. Z-Score can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area' with scores of less than 1 indicating the high probability of distress. Z Score is used widely by financial auditors, accountants, money managers, loan processers, wealth advisers, as well as day traders. In the last 25 years, many financial models that utilize z score has been proved to be successful as a predictor of corporate bankruptcy.
Pfizer Inc has Z Score of 1.8. This is 73.33% lower than that of the Healthcare sector, and significantly higher than that of Drug Manufacturers?General industry, The Z Score for all stocks is 79.36% higher than the company.
Did you try this?
Run Idea Analyzer Now
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
The Macroaxis Fundamental Analysis modules help investors analyze Pfizer Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pfizer using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pfizer Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way. Please read more on our fundamental analysis page.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies,
are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information
is derived directly from data published by
companies or submitted to governmental agencies which we believe are reliable, but are without our
independent verification. Therefore, we cannot assure you that the information is accurate or complete.
We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations.
Also, note that past performance is not necessarily indicative of future results. All investments carry risk,
and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee
that systems, indicators, or signals will result in profits or that they will not result in losses.
All investors are advised to fully understand all risks associated with any investing they choose to do.
Hypothetical or simulated performance is not indicative of future results.
We make no representations or warranties that any investor will, or is likely to, achieve profits
similar to those shown because hypothetical or simulated performance is not necessarily indicative
of future results. For more information please visit our
terms and condition page